Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Matinas BioPharma Holdings, Inc. (MTNB)

Matinas BioPharma ends former advisor agreement, pays $562,500 in cash

Neutral Impact 2 of 5 other Written later

Matinas BioPharma Holdings and a former financial advisor terminated their agreement on November 3, 2026. The agreement had provided for up to $2.0 million in cash and up to $2.0 million in stock tied to certain business combinations, and the company paid the advisor $562,500 in cash as part of the termination.

Key points

  • Agreement terminated November 3, 2026 between Matinas and a former financial advisor
  • Agreement had provided for up to $2.0 million in cash and up to $2.0 million in stock tied to certain business combinations
  • Company paid the advisor $562,500 in cash; the parties exchanged mutual releases, subject to certain contingencies

The filing

CompanyMatinas BioPharma Holdings, Inc. (MTNB)
Form8-K, current report
Filed with the SECNov 3, 2026, 4:30 PM ET
Accession number0001493152-26-049802

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.